img

Global Hormone Refractory Prostate Cancer Market Research Report 2024

Published on: 2024-01-04 | No of Pages : 400 | Industry : Medical

Publisher : MRA | Format : PDF

Global Hormone Refractory Prostate Cancer Market Research Report 2024

Hormone Refractory Prostate Cancer (HRPCA) or Castrate-Resistant Prostate Cancer (CRPC), a type of prostate cancer that typically recurs after having hormonal therapy, is now under the spotlight in prostate cancer market. Due to the high unmet clinical need associated with limited survival periods, intensifying HRPCA prevalence and fast-emerging treatment modifications, the global HRPCA market is poised to witness an unprecedented growth.
According to MRAResearch’s new survey, global Hormone Refractory Prostate Cancer market is projected to reach US$ million in 2033, increasing from US$ million in 2022, with the CAGR of % during the period of 2023 to 2033. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Hormone Refractory Prostate Cancer market research.
Key companies engaged in the Hormone Refractory Prostate Cancer industry include Astellas Inc, Sanofi S.A, Dendreon Corporation, Bayer AG and Johnson & Johnson, etc. Among those companies, the top 3 players guaranteed % supply worldwide in 2022.
When refers to consumption region, % value of Hormone Refractory Prostate Cancer were sold to North America, Europe and Asia Pacific in 2022. Moreover, China, plays a key role in the whole Hormone Refractory Prostate Cancer market and estimated to attract more attentions from industry insiders and investors.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2033), aims to help readers to get a comprehensive understanding of global Hormone Refractory Prostate Cancer market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.



By Company


Astellas Inc
Sanofi S.A
Dendreon Corporation, Bayer AG
Johnson & Johnson
Segment by Type
Chemotherapy
Hormonal Therapy
Immunotherapy
Radiation Therapy

Segment by Application


Hospitals
Ambulatory Surgical Centers
Specialty Clinics
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
The Hormone Refractory Prostate Cancer report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Global market size, regional market size. Market Opportunities and Challenges
Chapter 3Companies’ Competition Patterns
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6 to 10Country Level Value Analysis
Chapter 11Companies' Outline
Chapter 12Market Conclusions
Chapter 13Research Methodology and Data Source

Table of Content

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Hormone Refractory Prostate Cancer Market Size Growth Rate by Type: 2018 VS 2022 VS 2033
1.2.2 Chemotherapy
1.2.3 Hormonal Therapy
1.2.4 Immunotherapy
1.2.5 Radiation Therapy
1.3 Market by Application
1.3.1 Global Hormone Refractory Prostate Cancer Market Growth by Application: 2018 VS 2022 VS 2033
1.3.2 Hospitals
1.3.3 Ambulatory Surgical Centers
1.3.4 Specialty Clinics
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Hormone Refractory Prostate Cancer Market Perspective (2018-2033)
2.2 Hormone Refractory Prostate Cancer Growth Trends by Region
2.2.1 Global Hormone Refractory Prostate Cancer Market Size by Region: 2018 VS 2022 VS 2033
2.2.2 Hormone Refractory Prostate Cancer Historic Market Size by Region (2018-2023)
2.2.3 Hormone Refractory Prostate Cancer Forecasted Market Size by Region (2024-2033)
2.3 Hormone Refractory Prostate Cancer Market Dynamics
2.3.1 Hormone Refractory Prostate Cancer Industry Trends
2.3.2 Hormone Refractory Prostate Cancer Market Drivers
2.3.3 Hormone Refractory Prostate Cancer Market Challenges
2.3.4 Hormone Refractory Prostate Cancer Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Hormone Refractory Prostate Cancer Players by Revenue
3.1.1 Global Top Hormone Refractory Prostate Cancer Players by Revenue (2018-2023)
3.1.2 Global Hormone Refractory Prostate Cancer Revenue Market Share by Players (2018-2023)
3.2 Global Hormone Refractory Prostate Cancer Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Hormone Refractory Prostate Cancer Revenue
3.4 Global Hormone Refractory Prostate Cancer Market Concentration Ratio
3.4.1 Global Hormone Refractory Prostate Cancer Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Hormone Refractory Prostate Cancer Revenue in 2022
3.5 Hormone Refractory Prostate Cancer Key Players Head office and Area Served
3.6 Key Players Hormone Refractory Prostate Cancer Product Solution and Service
3.7 Date of Enter into Hormone Refractory Prostate Cancer Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Hormone Refractory Prostate Cancer Breakdown Data by Type
4.1 Global Hormone Refractory Prostate Cancer Historic Market Size by Type (2018-2023)
4.2 Global Hormone Refractory Prostate Cancer Forecasted Market Size by Type (2024-2033)
5 Hormone Refractory Prostate Cancer Breakdown Data by Application
5.1 Global Hormone Refractory Prostate Cancer Historic Market Size by Application (2018-2023)
5.2 Global Hormone Refractory Prostate Cancer Forecasted Market Size by Application (2024-2033)
6 North America
6.1 North America Hormone Refractory Prostate Cancer Market Size (2018-2033)
6.2 North America Hormone Refractory Prostate Cancer Market Growth Rate by Country: 2018 VS 2022 VS 2033
6.3 North America Hormone Refractory Prostate Cancer Market Size by Country (2018-2023)
6.4 North America Hormone Refractory Prostate Cancer Market Size by Country (2024-2033)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Hormone Refractory Prostate Cancer Market Size (2018-2033)
7.2 Europe Hormone Refractory Prostate Cancer Market Growth Rate by Country: 2018 VS 2022 VS 2033
7.3 Europe Hormone Refractory Prostate Cancer Market Size by Country (2018-2023)
7.4 Europe Hormone Refractory Prostate Cancer Market Size by Country (2024-2033)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Hormone Refractory Prostate Cancer Market Size (2018-2033)
8.2 Asia-Pacific Hormone Refractory Prostate Cancer Market Growth Rate by Region: 2018 VS 2022 VS 2033
8.3 Asia-Pacific Hormone Refractory Prostate Cancer Market Size by Region (2018-2023)
8.4 Asia-Pacific Hormone Refractory Prostate Cancer Market Size by Region (2024-2033)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Hormone Refractory Prostate Cancer Market Size (2018-2033)
9.2 Latin America Hormone Refractory Prostate Cancer Market Growth Rate by Country: 2018 VS 2022 VS 2033
9.3 Latin America Hormone Refractory Prostate Cancer Market Size by Country (2018-2023)
9.4 Latin America Hormone Refractory Prostate Cancer Market Size by Country (2024-2033)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Hormone Refractory Prostate Cancer Market Size (2018-2033)
10.2 Middle East & Africa Hormone Refractory Prostate Cancer Market Growth Rate by Country: 2018 VS 2022 VS 2033
10.3 Middle East & Africa Hormone Refractory Prostate Cancer Market Size by Country (2018-2023)
10.4 Middle East & Africa Hormone Refractory Prostate Cancer Market Size by Country (2024-2033)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Astellas Inc
11.1.1 Astellas Inc Company Detail
11.1.2 Astellas Inc Business Overview
11.1.3 Astellas Inc Hormone Refractory Prostate Cancer Introduction
11.1.4 Astellas Inc Revenue in Hormone Refractory Prostate Cancer Business (2018-2023)
11.1.5 Astellas Inc Recent Development
11.2 Sanofi S.A
11.2.1 Sanofi S.A Company Detail
11.2.2 Sanofi S.A Business Overview
11.2.3 Sanofi S.A Hormone Refractory Prostate Cancer Introduction
11.2.4 Sanofi S.A Revenue in Hormone Refractory Prostate Cancer Business (2018-2023)
11.2.5 Sanofi S.A Recent Development
11.3 Dendreon Corporation, Bayer AG
11.3.1 Dendreon Corporation, Bayer AG Company Detail
11.3.2 Dendreon Corporation, Bayer AG Business Overview
11.3.3 Dendreon Corporation, Bayer AG Hormone Refractory Prostate Cancer Introduction
11.3.4 Dendreon Corporation, Bayer AG Revenue in Hormone Refractory Prostate Cancer Business (2018-2023)
11.3.5 Dendreon Corporation, Bayer AG Recent Development
11.4 Johnson & Johnson
11.4.1 Johnson & Johnson Company Detail
11.4.2 Johnson & Johnson Business Overview
11.4.3 Johnson & Johnson Hormone Refractory Prostate Cancer Introduction
11.4.4 Johnson & Johnson Revenue in Hormone Refractory Prostate Cancer Business (2018-2023)
11.4.5 Johnson & Johnson Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

List of Figure

List of Tables
Table 1. Global Hormone Refractory Prostate Cancer Market Size Growth Rate by Type (US$ Million): 2018 VS 2022 VS 2033
Table 2. Key Players of Chemotherapy
Table 3. Key Players of Hormonal Therapy
Table 4. Key Players of Immunotherapy
Table 5. Key Players of Radiation Therapy
Table 6. Global Hormone Refractory Prostate Cancer Market Size Growth by Application (US$ Million): 2018 VS 2022 VS 2033
Table 7. Global Hormone Refractory Prostate Cancer Market Size by Region (US$ Million): 2018 VS 2022 VS 2033
Table 8. Global Hormone Refractory Prostate Cancer Market Size by Region (2018-2023) & (US$ Million)
Table 9. Global Hormone Refractory Prostate Cancer Market Share by Region (2018-2023)
Table 10. Global Hormone Refractory Prostate Cancer Forecasted Market Size by Region (2024-2033) & (US$ Million)
Table 11. Global Hormone Refractory Prostate Cancer Market Share by Region (2024-2033)
Table 12. Hormone Refractory Prostate Cancer Market Trends
Table 13. Hormone Refractory Prostate Cancer Market Drivers
Table 14. Hormone Refractory Prostate Cancer Market Challenges
Table 15. Hormone Refractory Prostate Cancer Market Restraints
Table 16. Global Hormone Refractory Prostate Cancer Revenue by Players (2018-2023) & (US$ Million)
Table 17. Global Hormone Refractory Prostate Cancer Market Share by Players (2018-2023)
Table 18. Global Top Hormone Refractory Prostate Cancer Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Hormone Refractory Prostate Cancer as of 2022)
Table 19. Ranking of Global Top Hormone Refractory Prostate Cancer Companies by Revenue (US$ Million) in 2022
Table 20. Global 5 Largest Players Market Share by Hormone Refractory Prostate Cancer Revenue (CR5 and HHI) & (2018-2023)
Table 21. Key Players Headquarters and Area Served
Table 22. Key Players Hormone Refractory Prostate Cancer Product Solution and Service
Table 23. Date of Enter into Hormone Refractory Prostate Cancer Market
Table 24. Mergers & Acquisitions, Expansion Plans
Table 25. Global Hormone Refractory Prostate Cancer Market Size by Type (2018-2023) & (US$ Million)
Table 26. Global Hormone Refractory Prostate Cancer Revenue Market Share by Type (2018-2023)
Table 27. Global Hormone Refractory Prostate Cancer Forecasted Market Size by Type (2024-2033) & (US$ Million)
Table 28. Global Hormone Refractory Prostate Cancer Revenue Market Share by Type (2024-2033)
Table 29. Global Hormone Refractory Prostate Cancer Market Size by Application (2018-2023) & (US$ Million)
Table 30. Global Hormone Refractory Prostate Cancer Revenue Market Share by Application (2018-2023)
Table 31. Global Hormone Refractory Prostate Cancer Forecasted Market Size by Application (2024-2033) & (US$ Million)
Table 32. Global Hormone Refractory Prostate Cancer Revenue Market Share by Application (2024-2033)
Table 33. North America Hormone Refractory Prostate Cancer Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2033
Table 34. North America Hormone Refractory Prostate Cancer Market Size by Country (2018-2023) & (US$ Million)
Table 35. North America Hormone Refractory Prostate Cancer Market Size by Country (2024-2033) & (US$ Million)
Table 36. Europe Hormone Refractory Prostate Cancer Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2033
Table 37. Europe Hormone Refractory Prostate Cancer Market Size by Country (2018-2023) & (US$ Million)
Table 38. Europe Hormone Refractory Prostate Cancer Market Size by Country (2024-2033) & (US$ Million)
Table 39. Asia-Pacific Hormone Refractory Prostate Cancer Market Size Growth Rate by Region (US$ Million): 2018 VS 2022 VS 2033
Table 40. Asia-Pacific Hormone Refractory Prostate Cancer Market Size by Region (2018-2023) & (US$ Million)
Table 41. Asia-Pacific Hormone Refractory Prostate Cancer Market Size by Region (2024-2033) & (US$ Million)
Table 42. Latin America Hormone Refractory Prostate Cancer Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2033
Table 43. Latin America Hormone Refractory Prostate Cancer Market Size by Country (2018-2023) & (US$ Million)
Table 44. Latin America Hormone Refractory Prostate Cancer Market Size by Country (2024-2033) & (US$ Million)
Table 45. Middle East & Africa Hormone Refractory Prostate Cancer Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2033
Table 46. Middle East & Africa Hormone Refractory Prostate Cancer Market Size by Country (2018-2023) & (US$ Million)
Table 47. Middle East & Africa Hormone Refractory Prostate Cancer Market Size by Country (2024-2033) & (US$ Million)
Table 48. Astellas Inc Company Detail
Table 49. Astellas Inc Business Overview
Table 50. Astellas Inc Hormone Refractory Prostate Cancer Product
Table 51. Astellas Inc Revenue in Hormone Refractory Prostate Cancer Business (2018-2023) & (US$ Million)
Table 52. Astellas Inc Recent Development
Table 53. Sanofi S.A Company Detail
Table 54. Sanofi S.A Business Overview
Table 55. Sanofi S.A Hormone Refractory Prostate Cancer Product
Table 56. Sanofi S.A Revenue in Hormone Refractory Prostate Cancer Business (2018-2023) & (US$ Million)
Table 57. Sanofi S.A Recent Development
Table 58. Dendreon Corporation, Bayer AG Company Detail
Table 59. Dendreon Corporation, Bayer AG Business Overview
Table 60. Dendreon Corporation, Bayer AG Hormone Refractory Prostate Cancer Product
Table 61. Dendreon Corporation, Bayer AG Revenue in Hormone Refractory Prostate Cancer Business (2018-2023) & (US$ Million)
Table 62. Dendreon Corporation, Bayer AG Recent Development
Table 63. Johnson & Johnson Company Detail
Table 64. Johnson & Johnson Business Overview
Table 65. Johnson & Johnson Hormone Refractory Prostate Cancer Product
Table 66. Johnson & Johnson Revenue in Hormone Refractory Prostate Cancer Business (2018-2023) & (US$ Million)
Table 67. Johnson & Johnson Recent Development
Table 68. Research Programs/Design for This Report
Table 69. Key Data Information from Secondary Sources
Table 70. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Hormone Refractory Prostate Cancer Market Size Comparison by Type (2023-2033) & (US$ Million)
Figure 2. Global Hormone Refractory Prostate Cancer Market Share by Type: 2022 VS 2033
Figure 3. Chemotherapy Features
Figure 4. Hormonal Therapy Features
Figure 5. Immunotherapy Features
Figure 6. Radiation Therapy Features
Figure 7. Global Hormone Refractory Prostate Cancer Market Size Comparison by Application (2023-2033) & (US$ Million)
Figure 8. Global Hormone Refractory Prostate Cancer Market Share by Application: 2022 VS 2033
Figure 9. Hospitals Case Studies
Figure 10. Ambulatory Surgical Centers Case Studies
Figure 11. Specialty Clinics Case Studies
Figure 12. Hormone Refractory Prostate Cancer Report Years Considered
Figure 13. Global Hormone Refractory Prostate Cancer Market Size (US$ Million), Year-over-Year: 2018-2033
Figure 14. Global Hormone Refractory Prostate Cancer Market Size, (US$ Million), 2018 VS 2022 VS 2033
Figure 15. Global Hormone Refractory Prostate Cancer Market Share by Region: 2022 VS 2033
Figure 16. Global Hormone Refractory Prostate Cancer Market Share by Players in 2022
Figure 17. Global Top Hormone Refractory Prostate Cancer Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Hormone Refractory Prostate Cancer as of 2022)
Figure 18. The Top 10 and 5 Players Market Share by Hormone Refractory Prostate Cancer Revenue in 2022
Figure 19. North America Hormone Refractory Prostate Cancer Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 20. North America Hormone Refractory Prostate Cancer Market Share by Country (2018-2033)
Figure 21. United States Hormone Refractory Prostate Cancer Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 22. Canada Hormone Refractory Prostate Cancer Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 23. Europe Hormone Refractory Prostate Cancer Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 24. Europe Hormone Refractory Prostate Cancer Market Share by Country (2018-2033)
Figure 25. Germany Hormone Refractory Prostate Cancer Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 26. France Hormone Refractory Prostate Cancer Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 27. U.K. Hormone Refractory Prostate Cancer Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 28. Italy Hormone Refractory Prostate Cancer Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 29. Russia Hormone Refractory Prostate Cancer Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 30. Nordic Countries Hormone Refractory Prostate Cancer Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 31. Asia-Pacific Hormone Refractory Prostate Cancer Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 32. Asia-Pacific Hormone Refractory Prostate Cancer Market Share by Region (2018-2033)
Figure 33. China Hormone Refractory Prostate Cancer Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 34. Japan Hormone Refractory Prostate Cancer Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 35. South Korea Hormone Refractory Prostate Cancer Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 36. Southeast Asia Hormone Refractory Prostate Cancer Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 37. India Hormone Refractory Prostate Cancer Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 38. Australia Hormone Refractory Prostate Cancer Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 39. Latin America Hormone Refractory Prostate Cancer Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 40. Latin America Hormone Refractory Prostate Cancer Market Share by Country (2018-2033)
Figure 41. Mexico Hormone Refractory Prostate Cancer Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 42. Brazil Hormone Refractory Prostate Cancer Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 43. Middle East & Africa Hormone Refractory Prostate Cancer Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 44. Middle East & Africa Hormone Refractory Prostate Cancer Market Share by Country (2018-2033)
Figure 45. Turkey Hormone Refractory Prostate Cancer Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 46. Saudi Arabia Hormone Refractory Prostate Cancer Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 47. Astellas Inc Revenue Growth Rate in Hormone Refractory Prostate Cancer Business (2018-2023)
Figure 48. Sanofi S.A Revenue Growth Rate in Hormone Refractory Prostate Cancer Business (2018-2023)
Figure 49. Dendreon Corporation, Bayer AG Revenue Growth Rate in Hormone Refractory Prostate Cancer Business (2018-2023)
Figure 50. Johnson & Johnson Revenue Growth Rate in Hormone Refractory Prostate Cancer Business (2018-2023)
Figure 51. Bottom-up and Top-down Approaches for This Report
Figure 52. Data Triangulation
Figure 53. Key Executives Interviewed

Select User License

$4200 Single Licence
$6000 Enterprise Licence
$9100 Corporate Licence
Note : All prices in USD

FAQ'S

User License?

For a single, multi and corporate client license, the report will be available in PDF format. Sample report would be given you in excel format. For more questions please contact:

sales@mraccuracyreports.com

Within 24 to 48 hrs.

You can contact Sales team (sales@mraccuracyreports.com) and they will direct you on email

You can order a report by selecting payment methods, which is bank wire or online payment through any Debit/Credit card, Razor pay or PayPal.

Discounts are available.

Hard Copy

Email

Top Industries